ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease
ProQR Therapeutics NASDAQ: PRQR said its first-in-human data for AX-0810 provided dose-dependent evidence that its RNA-editing approach can modulate NTCP, a liver transporter involved in bile acid uptake. The company is developing NTCP programs for cholestatic liver diseases, initially focusing on pediatric biliary atresia.
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript
ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other Catalysts
I initiate ProQR Therapeutics N.V. with a Buy rating, driven by strong initial human proof-of-concept for its Axiomer RNA editing platform. The company's AX-0810 achieved 8-fold serum bile acid increases in phase 1, surpassing the 2-fold target and supporting its disease-modifying potential in biliary atresia [BA]. Upcoming catalysts include full phase 1 data for AX-0810 by end-2026, pediatric BA data from China in H1 2027, and phase 1 data for next-gen AX-0811 by end-2026.
ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis
ProQR Therapeutics (PRQR) has transitioned its RNA editing platform from preclinical promise to demonstrated human pharmacological activity, notably with AX-0810's Phase 1 target engagement data. PRQR differentiates itself by prioritizing NTCP modulation in rare pediatric liver disease (biliary atresia), aiming for a faster, cleaner clinical validation path than competitors. Recent financings, including a $50M direct offering and Eli Lilly's $9.2M investment, extend PRQR's cash runway to mid-2027, supporting multiple clinical programs.
Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline
ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript
ProQR Therapeutics N.V. (PRQR) Presents at The Citizens Life Sciences Conference 2026 Transcript
ProQR Therapeutics N.V. (PRQR) Presents at The Citizens Life Sciences Conference 2026 Transcript
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
ProQR (PRQR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.1 per share a year ago.
ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates
ProQR (PRQR) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.11 per share a year ago.
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript
ProQR Therapeutics N.V. ( PRQR ) Shareholder/Analyst Call November 3, 2025 10:00 AM EST Company Participants Sarah Kiely - Vice President of Investor Relations & Corporate Communications Daniel de Boer - Founder, CEO & Member of Management Board Cristina Lopez Lopez - Chief Medical Officer Dennis Hom - Chief Financial Officer Gerard Platenburg - Co-Founder, Chief Scientific Officer & Member of Management Board Conference Call Participants Henkjan Verkade Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Ryan Deschner - Raymond James & Associates, Inc., Research Division Andreas Argyrides - Oppenheimer & Co. Inc., Research Division Kaey Nakae - Chardan Capital Markets, LLC, Research Division Catherine Novack - JonesTrading Institutional Services, LLC, Research Division Ananda Ghosh - H.C.
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
ProQR (PRQR) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.08 per share a year ago.
